Related Experiment Video
Updated: Feb 3, 2026
Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
Published on: September 8, 2023
Updates in CKD-Associated Osteoporosis
Pascale Khairallah1, Thomas L Nickolas2
1Division of Nephrology, Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH2-124, New York City, NY, 10032, USA.
Insights
Chronic kidney disease (CKD) increases osteoporosis and fracture risk. Early screening and tailored management strategies are crucial for patients with CKD to prevent bone loss and fractures.
Area of Science:
- Nephrology
- Endocrinology
- Bone Metabolism
Background:
- Chronic kidney disease (CKD) is strongly linked to significant bone loss and an increased risk of fractures.
- CKD-associated osteoporosis presents unique challenges in diagnosis and management for clinicians.
Purpose of the Study:
- To provide a comprehensive overview of the pathogenesis of osteoporosis in CKD patients.
- To summarize current diagnostic tools and therapeutic strategies for CKD-associated osteoporosis.
Main Methods:
- Review of updated 2017 Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
- Discussion of screening protocols including dual-energy X-ray absorptiometry (DXA).
- Evaluation of methods for assessing bone turnover (imaging, biochemical tests, bone biopsy).
Main Results:
- Updated guidelines recommend screening for osteoporosis and fracture risk in CKD patients.
- Management strategies post-diagnosis remain unclear for nephrologists.
- Bone turnover assessment can inform therapeutic choices.
Conclusions:
- Screening for CKD-associated osteoporosis is essential.
- Proactive strategies to prevent bone loss and fractures should be implemented.
- Further randomized controlled trials are necessary to establish treatment efficacy and safety.
Purpose Of Review:
Chronic kidney disease (CKD) is associated with bone loss and fractures. The purpose of this review is to provide clinicians with an overview of the underlying pathogenesis of CKD-associated osteoporosis, and a summary of the current diagnostic and therapeutic approaches to this disease.
Recent Findings:
In 2017, the Kidney Disease Improving Global Outcomes Committee on Bone Quality updated their guidelines to include screening for osteoporosis and fracture risk by dual energy X-ray absorptiometry in patients with CKD. Once a diagnosis of osteoporosis and/or fracture risk is established, it is not clear how nephrologists should manage their patients. Patients with CKD should be screened for CKD-associated osteoporosis and considered for strategies that prevent bone loss and fractures. Assessment of bone turnover via imaging, biochemical testing, or bone biopsy can help guide the choice of therapy. Randomized controlled trials are needed to assess safety and efficacy of treatments to prevent bone loss and fractures.
More Related Videos
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
